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In the context of aging populations in developed countries, researches related to 
erectile dysfunction (ED) are an important issue in modern science.  
According to Massachusetts Male Aging Study, the mean probability of 
some degree of ED was 52% in the whole group of 1,290 men aged from 40 to 
70 years (Feldman et al., 1994). In the USA, 6 million prescriptions for silde-
nafil were prescribed in the first 8 months after it became available (Morgentaler, 
1999). According to the European Male Ageing Study, erectile dysfunction was 
reported in 30% of the entire study. It was higher in the older age groups, espe-
cially in men 70 years and older (64%) (Vasan, 2010). Until the early 1990s, 
ED was thought to be related with the natural aging process and was tolerated 
together with other age-related diseases. Extensive studies in this area have 
shown that ED is not just an age-related phenomenon (Solomon et al., 2005). 
A large number of older men experience changes in the level of different 
sex hormones. The proportion of men with serum luteinizing hormone 
(LH) > 6.0 IU/L with normal serum testosterone > 9.8 nmol/L increases with 
age (Härkönen et al., 2003). It is possible that high LH levels in aging men may 
have an impact on the penile tissue and are thereby related to the development 
of erectile dysfunction. The prerequisite for such hypothesis would be the 
expression of LHCG receptors in the penis. 
Luteinizing hormone belongs to a family of glycoprotein hormones and has 
an important role in reproduction, having its receptor in the Leydig cells in the 
testis but also in ovarian theca, granulosa, luteal and interstitial cells (McFarland 
et al., 1989).  
The luteinizing hormone receptor (LHR), the follicle-stimulating hormone 
receptor (FSHR) and the structurally homologous thyroid stimulating hormone 
receptor (TSHR) form a glycoprotein hormone receptor subfamily that belongs 
to a large group of G protein-coupled receptors (GPCRs). Pituitary LH and pla-
cental choriogonadotropin both bind to LHR (Huhtaniemi and Alevizaki, 2006). 
Besides male and female gonadal cells, LHCGR has been found to be present in 
many nongonadal tissues described below, but its expression in the penis has 
never been studied before the present project.  
Studies on nongonadal LH/hCG actions may increase the possibilities of 
using these hormones in new clinical indications in the future (Rahman and Rao, 
2009). 
In the present thesis, the expression of LHCG receptors in the mouse and 
the human penis is studied to analyse the possible involvement of LH in the 
development of erectile dysfunction. As it is known that LH mediates its ste-
roidogenic actions through adenylate cyclase signaling pathway (Dufau et al., 
1984), the presence of adenosine 3',5'-cyclic monophosphate (cAMP) and 
cAMP-response element-binding protein (CREB), two components of this 
pathway, is also investigated in the penile tissue. 
 
10 
2. REVIEW OF LITERATURE 
2.1 Structure of the penis and the erectile mechanism 
2.1.1 Structure of the penis 
Penis is the male copulatory organ, but also the main part of the male urethra 
courses through it.  
The weight of the penis is supported by the fundiform ligament from the 
inferior part of the linea alba and the suspensory ligament from the pubic 
symphysis. The penis is cylindrical in shape and has three main parts: body, 
root and glans. The body also consists of three cylindrical masses, the paired 
dorsolateral masses are corpora cavernosa and the smaller midventral mass, the 
corpus spongiosum penis, includes the spongy urethra and keeps it open during 
ejaculation (Tortora, 1995). The bodies are encased by fascial layers of the 
tunica albuginea – Buck’s fascia and Colles’ fascia – which separate the corporeal 
sinusoids from the dermis and skin layer (Hsieh et al., 2012).  
The tunica albuginea of the corpora cavernosa is a bilayered structure, which 
has multiple sublayers. The collagen bundles of the inner layer are oriented 
circularly, supporting and containing the cavernous tissue. Bundles of the outer 
layer are directed longitudinally (Hsu et al., 1992). Corpus spongiosum has a 
much thinner tunica albuginea and contains more elastic fibers (Andersson and 
Wagner, 1995). 
The proximal ends of the corpora cavernosa, known as the crura, are anchored 
to the descending rami of the pubic arch. Cruras are covered by the ischio-
cavernous muscle, which can direct blood from the crus into the penis shaft. 
Beneath the symphysis, the two crura unite into one unpaired body. An 
incomplete fibrous partition, the septum penis, runs in the midline along the 
entire length of the corpus cavernosum penis.  
Corpus spongiosum penis is embedded in a longitudinal groove, which runs 
along the undersurface of the corpus cavernosum penis. It begins as bulbus 
penis, covered by the bulbospongiosus muscle. Bulbospongiosus muscle helps 
to squeeze out the contents from the urethra (Kahle et al., 1993). 
The erectile tissue of the penis has many endothelially lined spaces which 
are variably shaped and separated from one another by trabeculae of connective 
tissue and smooth muscle cells (Gartner, 2016). 
The corpora cavernosa contain numerous wide, irregularly shaped vascular 
spaces lined with vascular endothelium (Ross and Pawlina, 2011). The vascular 
spaces are smaller peripherally, near the tunica albuginea, and larger centrally 
(Gartner, 2016). 
A thin layer of smooth muscle surrounds the spaces and forms trabeculae 
within the tunica albuginea interconnecting and crisscrossing the corpus 
cavernosum. Many nerve endings and lymphatic vessels are in the interstitial 
connective tissue (Ross and Pawlina, 2011). 
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In corpus spongiosum, the vascular spaces are similar in size throughout its 
extent. Compared to corpora cavernosa, the trabeculae of the corpus spongiosum 
contain more elastic fibers and fewer smooth muscle cells (Gartner, 2016). 
Branches of the deep and dorsal arteries of the penis give blood to the erectile 
tissues of the corpora cavernosa. Penetrating the walls of the trabeculae of the 
erectile tissue, these branches form either capillary plexuses, which supply some 
blood flow into the vascular spaces, or helical arteries, which are important blood 
sources to the vascular spaces during erection of the penis (Gartner, 2016). 
Venous drainage of the corpora cavernosa is mainly via the cavernous veins, 
with additional drainage through the crural, circumflex and deep dorsal veins 
(Aboseif et al., 1989). 
 
 
2.1.2 Erectile mechanism 
Penile erection as a vascular event is initiated by the central nervous system and 
maintained by complex interactions between vascular and neurologic events. The 
central nervous system responds to external or internal stimuli involving the 
sympathetic and parasympathetic innervation of the penis. Parasympathetic 
stimulation initiates erection by relaxation of the trabecular smooth muscle cells 
and dilation of the helicine arteries. Sympathetic stimulation terminates penile 
erection by causing contraction of the trabecular smooth muscle cells of the 
helicine arteries (Ross and Pawlina, 2011).  
Many central neurotransmitters and neuropeptides also have a role in the 
erectile control. Serotonin, dopamine, oxytocin, nitric oxide (NO), adreno-
corticotropin/α-melanocyte stimulating hormone, excitatory amino acids and 
opioid peptides are some best-known central mediators which can facilitate or 
inhibit penile erection by acting in several brain areas (Andersson and Martin, 
2011). NO has a crucial role in the physiology of the penis and is an important 
factor for relaxation of vascular smooth muscles and smooth muscles of the 
corpus cavernosum (Burnett, 1995, 1997).  
The erection of the penis requires adequate filling of the corpora cavernosa 
with blood at systolic pressure or slightly above (Kirby, 1994). The cavernous 
smooth musculature and the smooth muscles of the arteriolar and arterial walls 
have an important role in the erectile mechanism. In a relaxed state, these muscles 
are in a state of contraction by the sympathetic discharge. Vasoconstrictors 
secreted by endothelium allow only a small amount of arterial flow for nutri-
tional purposes (El-Sakka and Lue, 2004). Relaxation of these muscles 
increases blood inflow into the lacunar spaces of the corpora cavernosa. The 
relaxed trabecular walls expand because of arterial pressure, thus expanding the 
tunica albuginea with elongation and compression of the draining venules, 
which restricts the outflow of blood. After ejaculation, the smooth muscle 
surrounding the arteries and the lacunar spaces contracts and the inflow of 
blood reduces. The penis returns then to a relaxed state because the venous 
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drainage of the corporeal spaces is opened again (Wagner and Saenz de Tejada, 
1998).  
The corpus spongiosum and the glans penis have somewhat different hemo-
dynamics compared to corpora cavernosa. Although the arterial flow increases in 
a similar manner during erection, the pressure in the corpus spongiosum and the 
glans is only one-third to one-half of that in the corpora cavernosa because of the 




2.2 Erectile dysfunction etiology 
Erectile dysfunction (ED) is an increasing health problem, which shows age-
dependent prevalence ranging from 2% in men younger than 40 years to 86% in 
men aged 80 years and older (Prins et al., 2002). It is predicted that by 2025 
over 322 million men are affected by erectile dysfunction world-wide (Ayta et al., 
1999). 
By definition, as given in the DSM-5 by the American Psychiatry Asso-
ciation (2013) erectile dysfunction is the inability to obtain and/or to maintain 
an adequate erection to enable satisfactory sexual activities. ED can be the result 
of many health conditions, including neurologic, psychogenic, vascular, uro-
genital and hormonal abnormalities but can also develop post-traumatically and 
after surgery (Celik et al., 2014). Potency disturbances possibly also have a 
genetic dimension, as e.g. expression of the DM1 protein kinase (DMPK) gene 
may be associated with many age-related signs, including hypogonadism and 
erectile disorders and there can be CTG repeat expansions in this gene affecting 
its function (Brisson et al., 2002). 
The problems with potency are usually multifactorial, but, generally, the dis-
orders resulting in erectile dysfunction can be subdivided into four groups: 
psychogenic, endocrinological, neurogenic and vascular impotence (Kirby, 1994).  
Predisposing factors related to the development of psychogenic erectile dys-
function are physical and mental health problems, traumatic past experiences, 
strict upbringing and inadequate sex education. Acute relationship problems, 
family or social pressures and major life events are also factors that may cause 
psychogenic erectile disorders (Shamloul and Ghanem, 2013). 
Although most cases of ED in men under 40 are thought to have psycho-
genic etiology, several studies have identified organic etiologies in men with ED 
in this age group, including vascular, neurogenic, endocrine disorders and also 
Peyronie’s disease or medication side effects (Ludwig and Phillips, 2014). 
Many neurological disorders may lead to erectile dysfunction, including 
cerebral insult, multiple sclerosis, spinal cord injury, Parkinson’s disease and 
Alzheimer’s disease. Radical pelvic surgeries are also risk factors for develop-
ment of erectile dysfunction. Endocrinological causes of erectile disorders are 
diabetes mellitus, hypogonadism and hyperprolactinaemia. Risk factors asso-
ciated with penile arterial insufficiency are atherosclerosis, hypertension, hyper-
13 
lipidaemia, diabetes mellitus, pelvic irradiation and cigarette smoking. Age, 
poor physical and psychological health, obesity, alcohol misuse, recreational 
drug use, sleep disorders, metabolic syndromes and also persistent medical 
disordes (chronic kidney, liver and pulmonary diseases) are all related to 
erectile dysfunction (Shamloul and Ghanem, 2013). 
 
 
2.3 The family of glycoprotein hormones and  
their receptors 
The first indication of the existence of gonadotropic substances in anterior 
pituitary extracts came from the pioneer work of Smith (1927) (Li and 
Pedersen, 1952). 
Gonadotropins as glycoprotein hormones are large (up to 40 kDa) proteins 
which regulate sexual development, normal growth and reproduction (Mazina et 
al., 2017). 
Luteinizing hormone (LH), thyroid-stimulating hormone (TSH), follicle-
stimulating hormone (FSH) and human choriogonadotropin (hCG) belong all to 
the family of glycoprotein hormones, the production of which occurs in the 
pituitary gland (LH, FSH, TSH) or in the placenta of a developing fetus (hCG) 
(Bousfield and Dias, 2011). As heterodimeric proteins, these hormones share a 
common α-subunit, and their hormonal specificity is determined by the β-chains 
(Tourkova et al., 2015). Both subunits are glycosylated in specific residues and 
are closely linked with disulfide bonds (Pierce and Parsons, 1981). A common 
α-subunit contains 92 amino acids, while β-subunits assign biological activity, 
displaying various degrees of homology, which, between hCG and LH, is 
approximately 80% (Stenman et al., 2006). 
Within family A of the G-protein-coupled receptors (GPCR), the thyroid-
stimulating hormone receptor (TSHR), follicle-stimulating hormone receptor 
(FSHR) and the luteinizing hormone/choriogonadotropin receptor (LHCGR) 
belong to the subfamily of glycoprotein-hormone receptors (GPHR) (Grzesik et 
al., 2014). There are mainly seven transmembrane helices, three extracellular 
and three intracellular loops and, in most, an intracellular C-terminal tail in the 
main structure of GPCRs (Puett et al., 2007). The interaction of the glycopro-
tein hormone with its receptor’s ectodomain leads to the activation of the 
receptor’s transmembrane domain for signal transduction (Dias et al., 2002). 
LH and hCG both bind to LHCGR (Puett et al., 2010). Polypeptides, which make 
hCG, form a group of three biologically important molecules with different 
physiological functions. These molecules are regular hCG, hyperglycosylated 
hCG and hyperglycosylated hCG free β-subunit. (Cole, 2009). The main role of 
hCG is to stimulate progesterone and oestrogen production in the corpus luteum 
(Hearn and Gomme, 2000). However, the understanding of the biological 
functions of hCG has developed significantly recently. For example, hCG 
maintains angiogenesis in the myometrial spiral arteries (Lei et al., 1992; Herr 
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et al., 2007), contributing to placental nutrient supply. The hyperglycosylated 
hCG regulates placental invasion, promotes cancer cell malignancy (Cole et al., 
2006) and is a critical factor for implantation (Sasaki et al., 2008). Hyper-
glycosylated hCG free β, made by non-trophoblastic cancer cells, enhances 
cancer cell growth and malignancy (Butler and Iles, 2003; Cole et al., 2006). 
FSH and LH regulate the spermatogenesis and steroidogenesis in the testes. 
While LH mainly controls the testosterone (T) secretion from Leydig cells, the 
role of FSH in the male gonads is to interact with Sertoli cells, resulting in the 
production of proteins which control spermatogenesis. In the female, LH and 
FSH control follicular growth, ovulation, development of the corpus luteum and 
steroid production in the follicle and corpus luteum. TSH regulates the thyroid 
hormone (tri-iodothyronine T3 and thyroxine T4) production and secretion from 
the thyroid gland (Hearn and Gomme, 2000). 
 
 
2.4 Luteinizing hormone receptor and  
its role in Leydig cells 
Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are pituitary 
gonadotropic hormones, the pulsatile release of which is central in reproduction. 
These hormones regulate the gonadal function. In the testis, LH regulates the 
production and secretion of androgens by acting through plasma membrane 
receptors of the Leydig cells. In the testis, LHCGRs are expressed during the fetal 
life, postnatally, at puberty, and throughout adult life. LH also promotes the 
maturation of follicular cells in the ovary (Dufau, 1998). 
The luteinizing hormone/choriogonadotropin receptor (LHCGR) is a member 
of glycoprotein hormone receptors (GPHR) (Ascoli et al., 2002; Caltabiano et al., 
2008). LHCGR anchors within the cell membrane by seven transmembrane 
domains, and its gene is located on the short arm of chromosome 2 (2p21) 
(Rousseau-Merck et al., 1990, 1993). The human LHCGR gene contains 11 
exons and 10 introns, complemented by the primate-specific exon 6A (Atger et 
al., 1995; Kossack et al., 2008). Inactivating mutations of the LHCGR gene are 
LH receptor is expressed in many cell types, including the corpus luteal cells 
(Bukovsky et al., 2003), the decidual cells (Licht et al., 2003), the myometrial 
smooth muscle cells (Phillips et al., 2005), the uterine vascular cells (Toth et al., 
1994), the smooth muscle and endothelial cells of umbilical arteries and vein 
(Rao et al., 1993), the embryonic stem cells (Gallego et al., 2010), the tropho-
blasts (Prast et al., 2008), some of the brain cells (Bukovsky et al., 2003; Cole, 
2010), the testicular endothelial cells (Ghinea et al. 1994; Ghinea and Milgrom, 
2001), the human ejaculated spermatozoa (Elben et al., 2001) and also certain 
cells in oviducts, spinal cord, neural retina, skin, breast, adrenals, urinary bladder, 
bone, cavernous sinus carotid rete vascular complex, prostates, seminal vesicles 
and epididymides (Rao, 2001). 
also known (Latronico and Arnhold, 2012). 
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Released from the anterior pituitary gland in a pulsatile manner, LH controls, 
among its other functions, the androgen production by the Leydig cells, thus 
maintaining testosterone production at the necessary level through interaction 
with LH receptors and activation of the steroidogenic signal transduction path-
ways of the Leydig cell. LH receptor activation leads to the stimulation of 
adenylate cyclase in the Leydig cell plasma membrane, causing phosphorylation 
of the key intermediate of its signal transduction pathway. After up-regulation 
of testosterone production in the Leydig cells, increased circulating testosterone 
concentration down-regulates LH production, which again leads to upregulation 
of the LH receptors and vice versa, when lowering serum testosterone levels 
induce increased LH production – like in aging men (Härkönen et al., 2003) – 
or when hCG is given in high doses, LH receptor production may be down-
regulated to a certain degree (Dufau et al., 1984). 
 
 
2.5 cAMP and CREB and their role in signal transduction 
Adenosine 3',5'-cyclic monophosphate (cAMP), cyclic guanosine monophos-
phate (cGMP), nucleotides, lipids and other small molecules belong to the group 
of intracellular second messengers, which convert and magnify extracellular 
signals by activating protein kinases or acting on intracellular ligand-gated 
channels to alter membrane potential. One of the most important cyclic phosphate 
involved with signal transduction is cAMP (Yan et al., 2016). 
In response to tropic hormone, activation of the adenylate cyclase enzyme 
causes intracellular increase in cAMP and PKA (protein kinase A) activation 
(Stocco and Clark, 1996; Stojkov et al., 2014). Although cAMP mediates its 
intracellular effects mainly through PKA, it may also act via other target 
proteins, like Epacs (exchange proteins directly activated by cAMP) (de Rooij et 
al., 1998). 
After binding to its receptor, LH activates the adenylate cyclase enzyme, 
causing an increase in the production of cAMP from adenosine trisphosphate 
(ATP). The increased intracellular cAMP activates the cAMP-dependent protein 
kinase A (PKA). After translocation to the nucleus, the activated PKA parti-
cipates in the regulation of gene expression via phosphorylating transcription 
factors like cAMP-response element binding protein (CREB), which initiates 
transcription of cAMP-response genes by binding to the cAMP response element 
in the promoter region of the cAMP-response genes (Zeleznik and Somers, 
1999; Yan et al., 2016).  
The cAMP response element binding protein (CREB) belongs to a large 
family of DNA binding proteins (Priyanka and Medhamurthy, 2007), and it is the 
first transcription factor whose activity, together with its other family members, 
is known to be regulated by phosphorylation (Mayr and Montminy, 2001). 
CREB, CREM (cAMP response element modulator) and ATF-1 (activating tran-
scription factor-1) are genes that share wide homology, form the CREB/CREM 
subfamily and mediate transcriptional activation. This subfamily has an 
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important role in the growth and development processes of many organs, is 
necessary for survival and mediates various biological functions (Manna et al., 
2002). CREB regulates numerous genes with various functions, like proliferation, 
survival, memory and learning (Kinjo et al., 2005). 
 
 
2.6 Hormonal changes in aging men 
Although the gonadal function declines with age in both men and women, men 
have a more gradual decline in the gonadal function, which means there is no 
andropause equivalent of the menopause (Vermeulen, 2000).  
Hypogonadism is a clinical condition caused by a testicular failure to produce 
physiological levels of testosterone and a normal number of spermatozoa due to 
hypothalamic-pituitary-testicular axis disorder. Primary hypogonadism, also 
known as hypergonadotropic hypogonadism, can be a result of several testicular 
injuries, tumour, infection (Dandona and Rosenberg, 2010) or renal failure, 
hepatic cirrhosis, drugs, autoimmune disease and irradiation (Gurung and Jialal, 
2019). Despite high levels of LH and FSH, the gonads are unable to produce 
sufficient testosterone or spermatogenesis. It may also have congenital causes, 
such as androgen synthesis disorder, cryptorchidism or Klinefelter syndrome 
(Gurung and Jialal, 2019). The second form, which is more common and shows 
low T and low or inappropriately normal LH, is usually linked with overweight 
or chronic diseases (hypertension, diabetes, heart failure, metabolic syndrome, 
inflammatory arthritis, chronic obstructive lung disease etc.) (Huhtaniemi, 
2014). Congenital isolated gonadotropin-releasing hormone (GnRH), LH or 
FSH deficiency may also be the cause of secondary hypogonadism (Gurung and 
Jialal, 2019). Dual defects, affecting both the pituitary and the testis, are also 
possible. Depending on which defect predominates, combined failure results in 
variable gonadotropin levels, impaired spermatogenesis and low testosterone 
levels (Bhasin et al., 2010). The study results of Delhez et al., 2003 on 153 men 
(aged 50–70 years) showed a decrease in the levels of free T, whereas FSH and 
LH increased. In the “Hypogonadism in Males” study (in men aged ≥45 years), 
patients with hypertension, hyperlipidaemia, diabetes, obesity, prostate disease 
and asthma or chronic obstructive pulmonary disease had significantly higher 
odds of hypogonadism compared to patients without these comorbidities 
(Mulligan et al., 2006). According to Rey et al., 2013, male hypogonadism can 
be classified based on the pathophysiology of the hypothalamic-pituitary-
testicular axis in different life periods, considering the level of the hypothalamic-
pituitary-testicular axis primarily affected, the testicular cell population initially 





2.7 Summary of the literature 
Erectile dysfunction (ED) as an inability to achieve normal erection and also to 
maintain it sufficiently long, has a multifactorial etiology. It is an increasing 
health problem, especially in the context of an aging society. The general dis-
orders resulting in ED can be subdivided into psychogenic, neurogenic, vascular 
and endocrinological subgroups, but also many other risk factors can affect the 
development of ED. Endocrinological causes of erectile dysfunction include 
diabetes mellitus, hyperprolactinaemia and hypogonadism. Although large 
number of older men experience changes in the level of different sex hormones 
and ED shows age-dependent prevalence, it is not only an age-related phe-
nomenon. LH, TSH, FSH and hCG are all pituitary gonadotropic hormones, 
heterodimeric proteins, sharing a common α-subunit, while β-subunits determine 
hormonal specificity, assign biological activity and display various degrees of 
homology. LH mainly regulates gonadal function and exerts its actions through 
binding to its receptors and mediating its steroidogenic actions through adenylate 
cyclase signaling pathway. In the testis, LH regulates the production and secretion 
of androgens, mainly controlling the testosterone secretion from Leydig cells. 
LHCGR, together with FSHR and TSHR, belongs to a family of glycoprotein 
hormone receptors and besides gonadal cells it has found to be expressed in 
many extragonadal tissues. Until now there is no data about the expression of 
LH receptors in the penis. The study was started to find out if LH receptor is 
expressed in the penile tissue to analyse whether it could be involved in the 
pathogenesis of erectile dysfunction. Studies on the effects of nongonadal 
LH/hCG may increase the potential for these hormones to be used in new 
clinical indications in the future. 
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3. AIMS OF THE STUDY 
The general aim of the present study is to evaluate the expression of the LH 




1. To investigate the expression of the LH receptor in the mouse penis 
2. To evaluate the expression of the LH receptor in the human penis. 
3. To find out if cAMP and CREB, the components of LH signal transduction 
pathway, are expressed in the human penis. 
4. To analyse, based on the results of the study, if the elevated serum LH levels 
in aging men may have an impact on the corpus spongiosum and cavernosum 
penis and be related to the development of erectile dysfunction. 
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4. MATERIALS AND METHODS 
4.1 Materials 
4.1.1 Animals (Paper III) 
Balb/c mice (n=42) were used as donors of normal penis tissue and testis tissue 
(positive control). Fourteen mice (6–7 weeks old) were used for immunohisto-
chemistry; 20 mice (10–12 weeks old), for Western blotting; and 8 mice 
(15 weeks old), for qRT-PCR (Table 1). The mice used in the present study 
were bred and cared at the Animal Care Center of the University of Tampere, 
Finland. According to the national guidelines, no permission from the authorities 
was required to collect tissue specimens from sacrificed mice. The animals had 
free access to food and water, and they were maintained in a normal dark/light 
cycle. The mice penises and testes were removed after sacrificing the mice with 
CO2.  
The penis was collected up to the body wall and the distal two-thirds of the 
body of the penis was used for each analysis. The penis was cut, not prepared free 
of the surrounding tissue, so the visible part of penis was collected. 14 penises 
and 2 testes (from 2 mice) were collected for immunohistochemistry, fixed in 4% 
formalin and embedded in paraffin according to standard methods. A total of 
20 penises in one sample (0.62 g of penile tissue in 1.86 ml NaCl) and a total of 
40 testes in one sample (4.59 g of testis tissue in 13.5 ml NaCl) were examined 
for Western blotting. Altogether 8 penises (1 penis/1 ml Eurozol, weight approx-
imately 27–35 mg) and 6 testes (from 6 mice; 1 testicle/2.5 ml Eurozol, weight 
 
Table 1. Balb/c mice used as donors of penis tissue 
Mice (n=42) Age in weeks Study method 
14 6–7 immunohistochemistry 




4.1.2 Human penis tissue (Papers I and II) 
Penile tissue was obtained from three patients undergoing partial or total penec-
tomy either due to rectal cancer or squamous cell carcinoma of the penis. The 
patients were being treated at the Tampere University Hospital. 
Two patients (66-year-old and 64-year-old) were undergoing total penec-
tomy due to rectal cancer with secondary penile metastasis, and one 83-year-old 
patient with squamous cell carcinoma of the penis was undergoing partial 
penectomy. 
approximately 134–155 mg) were examined for qRT-PCR. 
20 
Samples from corpus cavernosum and corpus spongiosum penis were fixed 
in 4% formalin overnight at 4 °C. After fixation, the samples were stored in 70% 
ethanol until embedding in paraffin according to standard methods. 
 
 
 4.2 Methods 
4.2.1 Immunohistochemistry  
4.2.1.1 Avidin-Biotin Immunoperoxidase Method (Paper III) 
Paraffin sections of 5 µm in thickness were cut and mounted on poly- L-lysine 
coated Super-Frost slides (Menzel-Gläser, Germany). After deparafinization, 
endogenous peroxidase blockade (0.5% H2O2 in methanol) was carried out for 
30 min. Sections were washed in distilled water for 2 × 5 min and in phosphate 
buffered saline (PBS) 2 × 10 min. Slides were held in 0.01 M sodium citrate 
buffer (pH 6.0) in a microwave oven at 100 °C for 20 min. Sections were 
removed from heat and kept at room temperature in buffer for 20 min. After 
washing in Tris-buffered saline (TBS) for 5 min and in PBS for 5 min, non-
specific binding sites were blocked by incubating the sections in 10% normal 
goat serum (NGS) for 30 min. The sections were then incubated with the primary 
antibody or the control serum overnight at +4 °C. Rabbit polyclonal anti-LH 
receptor antibody (Acris Antibodies GmbH, Germany) was used as the primary 
antibody diluted 1:750 in 1% NGS in PBS. The sections were washed for 
3 × 10 min in PBS and incubated with goat anti-rabbit IgG (Acris Antibodies 
GmbH, Germany) for 30 min. The biotinylated secondary antibody was diluted 
1:500 in PBS containing 1% NGS. After 3 × 10 min washing in PBS, the sections 
were incubated with the ABC reagent for 30 min (reagent A 90 µl; 10 ml PBS+ 
reagent B 90 µl; Vector Laboratories Inc, Burlingame, California). The sections 
were washed for 3 × 10 min in PBS followed by a demonstration of peroxidase 
activity, using 3,3'-diaminobenzidine (DAB; Sigma) as a substrate. 
 
 
4.2.1.2 Peroxidase/DAB+ method with Dako REAL™ EnVision™  
Detection System (Paper I and II) 
Samples from corpus cavernosum and corpus spongiosum of the penis were 
embedded in paraffin after fixation in formalin. 5 µm sections were cut, 
deparaffinized and treated with 0.9% H2O2 to inactivate endogenous peroxidase. 
The sections were then treated with Dako REAL Antibody Diluent (S2022; 
Dako Denmark A/S, Glostrup, Denmark) to block non-specific binding. After 
blocking, the sections were incubated with the rabbit polyclonal antibody to 
luteinizing hormone receptor (LHCGR) (C-term) (SP4594P, Acris Antibodies), 
the mouse monoclonal antibody to cAMP (ab24851, Abcam) or the rabbit mono-
clonal antibody to CREB (ab32096, Abcam) overnight at 4 °C. Primary antibody 
dilution was 1:500 for luteinizing hormone receptor and 1:200 for cAMP and 
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CREB. Visualization of the primary antibody was performed using the com-
mercial kit “Dako REAL™ EnVision™ Detection System, Peroxidase/DAB+, 
Rabbit/Mouse” (K5007; Dako Denmark A/S, Glostrup, Denmark). Washing steps 
in-between were done in phosphate buffered saline (PBS) which contained 0.07% 
of Tween 20 as the detergent. Toluidine blue (Applichem, Darmstadt, Germany) 
was used for background staining. No immunohistochemical staining was noted 




4.2.3 Quantitative reverse transcriptase polymerase  
chain (qRT-PCR) reaction (Paper III) 
The penis and testis tissues were homogenized using 1 ml of Eurozol (Euroclone, 
S.p.A. Milano, Cat. #EMR055100) per penis and 2.5 ml of Eurozol per testis. 
Chloroform (0.1 ml) was added to each sample. Three samples were run. Samples 
were mixed carefully, incubated on wet ice for 5 minutes and centrifuged at 
 
4.2.2 Western blotting (Paper III) 
Penile and testis tissue homogenates were prepared in protease inhibitor suspen-
sion Complete Mini (Roche, # 11 836 153 001) in 0.9% NaCl. The tissue was 
placed in 6 ml of suspension buffer and homogenized. After incubation, the lysate 
was centrifuged at 250 x g for 15 min. The salts were removed from the 
supernatant, and the supernatant was centrifuged at 10000 x g for 30 min. The 
supernatant was collected, and the eluate was then freeze-dried at –70 °C. The 
protein was diluted to 1:2 in a solution of 10% sodium dodecyl sulfate (SDS), 
glycerol, 10% bromophenol blue and 5% β-mercaptoethanol in 0.5M TRIS 
buffer, pH 6.8. The samples were boiled for 5 min. 
Denaturated 7.5% SDS polyacrylamide mini-gels were prepared, and 50-µl 
samples were loaded into the wells. High-molecular-weight markers were run 
parallel to the samples. Gels were run with 100-mA current and after electro-
phoresis, proteins were transferred to a nitro-cellulose filter for 60 min using 
200-mA current. The nitro-cellulose filter was stained with Ponceau S and each 
separate line was cut off. The strips were blocked with TBS Blotto A (Santa Cruz, 
#SC-2333) for l hour at room temperature. Then the strips were incubated over-
night at 4 °C with anti-LH receptor antibody (Acris Antibodies GmbH, 
Germany, #SP4594P) diluted 1:3000 in TBS Blotto A. Normal rabbit immuno-
globulin G (IgG; Dako Cytomation, Denmark, #X 0903), diluted 1:3000 in TBS 
Blotto A, was used as negative control. After incubation, the strips were washed 
three times with TBS 0.05% Tween solution and then incubated for l hour in 
1:30000 dilution of horseradish peroxidase-conjugated goat anti-rabbit Ig (Acris 
Antibodies GmbH) in TBS Blotto A per strip. Strips were washed three times 
with TBS 0.05% Tween solution and then allowed to react with Amersham ECL 
Western Blotting Detection Reagents RPN 2106. Strips were blotted dry before 
photographing. 
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12000 x g for 15 min. The upper aqueous phase containing RNA was collected in 
a new tube, 500 µl of cold isopropanol was added and the mixture was stored in 
wet ice for 15 min. After centrifugation at 12000 x g for 15 min, the samples 
were washed, adding 1 ml 75% ethanol. Samples were centrifuged at 8000 x g 
for 15 min and dried.  
Relative quantification of LH in real-time RT-PCR was done using the Pfaffl 
model (Pfaffl, 2001). The cDNA was synthesized from the total RNA by RT-PCR 
using a High Capacity cDNA Archive kit (Applied Biosystems, Foster City, 
California). The reaction was performed at 37 °C for two hours. Samples were 
stored at –20 °C prior to the real-time PCR reaction. Expression of mRNA in the 
tissues was detected using real-time PCR. Target cDNA was amplified by PCR 
for 40 cycles (1 cycle: 95 °C for 15 seconds, 60 °C for 1 minute) in ABI PRISM® 
7000 SDS using SYBR® Green solution (Applied Biosystems) and 20 ng of 
template cDNA. The PCR primer sequences were: forward   
5’-TGTATGGAAATGGGTTTGAAGAAGT-3’, reverse   
5’-TTCTTTTAACTCCAGCGAGATTAGC-3’ for the mouse LH receptor gene 
and forward 5’-GCTTCTTTGCAGCTCCTTCGT-3’, reverse   
5’-CCAGCGCAGCGATATCG-3’ for the internal control gene mouse β-actin. 
Primers were designed by using Primer Express v2.0 software (Applied Bio-
systems). To avoid amplification of any genomic DNA, the forward and reverse 
primers for LH receptor gene were chosen from different exons. BLASTN 
searches were performed to confirm the specificity of the primer sequences. The 
final results, expressed as relative differences (ratio) in gene expression between 
samples, were calculated by using amplification efficiencies obtained from the 
standard curves and Ct values as described previously (Pfaffl, 2001). Ct is the 




5.1 Expression of the LH receptor  
in the mouse penis (Paper III) 
The results demonstrate the presence of the LH receptors in all investigated mice 




5.1.1 Immunohistochemistry  
Positive immunoreaction for LH receptors was found in the mouse penis in the 
urethral epithelium. Positive immunoreaction was also detected in the endothelial 
cells of the cavernous spaces both in corpus spongiosum and corpus cavernosum 
penis. All these kinds of positive cells were found in all investigated penises 
(Fig. 1A). No positive cells were present in negative controls (Fig. 1B).  
Figure 1. Expression of LHCG receptor in the mouse penis (A) and testis (C). Control 
sections of penis (B) and testis (D). UE – urethral epithelium; CS – corpus spongiosum 
penis; CC – corpus cavernosum penis; EC – endothelial cells of the cavernous spaces; 






Testis tissue was used as positive control for the detection of LH receptors in 
their target cells. Positive immunoreaction to the LH receptor was found in the 
Leydig cells and in the central part of seminiferous tubules next to the lumen, 
most likely in spermatozoas or in residual bodies (Fig. 1C). 
No positive cells were present in negative controls (Fig. 1D). 
 
 
5.1.2 Western blotting 
The LH receptor antigen was repeatedly present in the mouse penises investigated 
in Western blotting (Fig. 2). 
It was recognized at Mr = 97.4, occasionally, also at Mr = 78 kD. LH receptor 
antigen was present in the penile tissue.  
Testis tissue was used as positive control. The LH receptor antigen was 
repeatedly recognized at Mr = 97.4 and 78 kD.  
 
 





5.1.3 Quantitative reverse transcriptase polymerase  
chain (qRT-PCR) reaction 
LHR was specifically detected in the penis in qRT-PCR (Table 2). 
 
Table 2. Expression of the LHR in the penis in qRT-PCR 
 Ct (LHR) Ct (β-Actin) Ratio 
Penis 27.069 ± 0.049 17.921 ± 0.084 0.044 ± 0.005 
Testis 23.836 ± 0.099 19.381 ± 0.138 1.000 
Abbreviations: Ct, threshold cycle; LHR, luteinizing hormone receptor; qRT-PCR, quantitative 
reverse transcriptase polymerase chain reaction. 
 
 
5.2 Expression of the LH receptor  
in the human penis (Paper I) 
Positive immunoreaction was found in all three investigated penises. 
Positive immunoreaction for LHCG receptors was present in the endothelial 
cells of cavernous spaces in the corpus spongiosum (Fig. 3A) and cavernosum 
penis (Fig. 3B). Positive immunoreaction was present in fibroblast-like cells of 
interstitial tissue in the corpus spongiosum penis (Fig. 3A). Positive immuno-
reaction was also present in superficial, intermedial and basal layer of urethral 
epithelium and in fibroblast-like cells of interstitial tissue and endothelial cells 
of cavernous spaces in glans penis (Fig. 3C). Positive immunoreaction for LHCG 
receptors was detected in the endothelial cells of capillary walls (Fig. 3D).  
No positive cells were visible in negative controls (Fig. 6A). 
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Figure 3. Expression of LHCG receptors in the human penis. Corpus spongiosum penis 
(A), corpus cavernosum penis (B), glans penis (C) and capillary wall (D). EC – 
endothelial cells; ESL – superficial layer of urethral epithelium; EIL – intermedial layer 
of urethral epithelium; EBL – basal layer of urethral epithelium; FLC – fibroblast-like 
cells of interstitial tissue. Staining: DAB + toluidine blue. 
 
 
5.3 Expression of the cAMP and  
CREB in the human penis (Paper II) 
Positive immunoreaction for cAMP was present in most cells of superficial, 
intermedial and basal layer of urethral epithelium and in fibroblast-like cells of 
interstitial tissue and endothelial cells of cavernous spaces in corpus spongiosum 
penis (Fig. 4A). 
Positive staining for cAMP was also visible in endothelial cells of cavernous 
spaces and in fibroblast-like cells of interstitial tissue in corpus cavernosum penis 
(Fig. 4B). 
Positive immunoreaction for CREB was present in superficial and intermedial 
layer of urethral epithelium and some positive staining was also noticed in 
endothelial cells of cavernous spaces and in fibroblast-like cells of interstitial 
tissue in corpus spongiosum penis (Fig. 5A).  
Positive staining for CREB was also visible in endothelial cells of cavernous 
spaces and in fibroblast-like cells of interstitial tissue in corpus cavernosum 
penis (Fig. 5B). No positive cells were visible in negative controls (Fig. 6B). 
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Figure 4. Expression of cAMP in the human penis. Corpus spongiosum penis (A), 
corpus cavernosum penis (B). EC – endothelial cells; ESL – superficial layer of urethral 
epithelium; EIL – intermedial layer of urethral epithelium; EBL – basal layer of urethral 
epithelium; FLC – fibroblast-like cells of interstitial tissue. Staining: DAB + toluidine 
blue. 
Figure 5. Expression of CREB in the human penis. Corpus spongiosum penis (A), 
corpus cavernosum penis (B). EC – endothelial cells; ESL – superficial layer of urethral 
epithelium; EIL – intermedial layer of urethral epithelium; FLC – fibroblast-like cells of 
interstitial tissue. Staining: DAB + toluidine blue. 
 
Figure 6. Negative controls for LHCG receptors (A) and cAMP and CREB (B) in the 






Table 3. Expression of the LHR, cAMP and CREB in the different types of cells in the 
human penis 
 LHR cAMP CREB 
Corpus spongiosum penis  
Superficial layer of urethral epithelium + + + 
Intermedial layer of urethral epithelium + + + 
Basal layer of urethral epithelium + + N/A 
Fibroblast-like cells of interstitial tissue + + + 
Endothelial cells of cavernous spaces + + + 
Corpus cavernosum penis  
Endothelial cells of cavernous spaces + + + 
Fibroblast-like cells of interstitial tissue N/A + + 
N/A not available 
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6. DISCUSSION 
6.1 General discussion 
The results of our studies show that the LH receptor exists in both mouse and 
human penile tissue (Kokk et al., 2011; Zirnask et al., 2018). We also succeeded 
in showing the presence of the two components, cAMP and CREB, related to the 
adenylate cyclase signal transduction pathway used by the LH receptor, in the 
penis (Zirnask et al., 2019). These findings support the view that LH has a 
previously unknown role in the penis, and its elevated levels could also affect 
the tissue of the corpus cavernosum and spongiosum penis, thereby having a role 
in the pathogenesis of erectile dysfunction. 
It has been demonstrated that a significant proportion of aging men are in a 
subclinical hypogonadism with elevated serum LH concentrations (Härkonen et 
al., 2003; Foresta et al., 2015). As well the observations of Yu et al. (2017) con-
firmed the influence of increased age and LH on the aging male symptoms and 
on the 5-item version of the international index of erectile function scores. On 
the basis of the present results we may suggest that the chronically elevated LH 
in aging men might have an influence on the penile tissue through the penile 
LHCGR. This suggestion is supported by the previous results of the Turku 
Aging Male Study, as a statistically significant positive correlation was found 
between s-LH and the reported intensity of potency disturbances among aging 
men (Härkönen et al., 2003). Also according to the European Male Ageing Study, 
conducted on 3369 community-dwelling European men aged 40–79 years, men 
with incidentally high LH developed erectile dysfunction more often than men 
with persistently normal LH (Eendebak et al., 2018). 
Although LH or LHCGR have not been reported to be associated with 
erectile dysfunction in genome-wide analyses this far (Kerns et al., 2010; 
Hotaling et al., 2012; Kerns et al., 2013), the FSH receptor sharing the α-subunit 
and having homology in its β-subunit with the β-subunit of LH receptor has 
been (Kerns et al., 2010). It may be of importance here that the cumulus cells 
have been reported to express LH receptor mRNA in response to FSH (Hattori 
et al., 2000; Nishida et al., 2000), suggesting that the effects of the elevated LH 
levels in aging men may lead to effects in the penis only if the FSH levels are 
elevated as well, and they often are in aging males (Lee et al., 2010). Based on 
the present and earlier data, it might be possible that the increased LH and FSH 
levels may cause erectile dysfunction together. However, further research is 
needed to see how LH receptor expression is regulated in the penis. 
According to literature, the wild-type LHCG receptors and the wild-type 
FSH receptors can also form dimers (Segaloff, 2012), suggesting that the regu-
lation of the penile tissue by the gonadotrophins is more complex and still needs 
more research. 
The present findings also suggest that high female LH, hCG concentrations 
in the vaginal excretions might possibly affect the penile function if reaching 
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the LHCG receptors, as it is known that women have high serum LH levels after 
menopause (Edwards and Li, 2013) and high levels of hCG during pregnancy 
(Szczerba et al., 2016). 
Our present data about the presence of cAMP and CREB in the human penis 
(Zirnask et al., 2019), two components of the adenylate cyclase signal trans-
duction pathway used by the LH receptor, also support the possibility of potential 
actions of LH in the human penis, especially as the the expression of protein 
kinase A in the human penile tissue has been described before (Waldkirch et al., 
2010). 
As according to Cui et al., 2017, both the erectile function and the expression 
levels of cAMP were significantly lower in the aged than in the younger rats, it 
may be possible that elevated serum LH concentrations could act as a com-
pensatory mechanism to increase the levels of cAMP in the penile endothelial 
cells of aging men.  
Furthermore, it may be of interest that nitric oxide (NO), a substance known 
to affect the penile tissue, can affect FSH-induced LH receptor synthesis by 
granulosa cells (Nishida et al., 2000), and that LH has a significant stimulatory 
effect on NO synthase expression in vitro in a prostaglandin-dependent manner 
(Zamberlam et al., 2014). If the same mechanisms can be demonstrated in the 
penile LH receptor expressing cells at some point, we may understand much 
more about the regulation of the penile function and the cell biological back-
ground of erectile dysfunction.  
It should also be taken into account that LH production is regulated by several 
factors, not only testosterone itself and that potency itself is regulated by several 
cell biological mechanisms, not only by LH action. Especially, it is interesting 
that although the proportion of men with serum LH in the uppermost quartile 
(> 6.0 IU/L) and serum testosterone above the lowest 10 % (> 9.8 nmol/L) was 
statistically significantly associated with age (11, 24 and 31 % among 41–50, 
51–60 and 61–70-year-old men, respectively, Härkönen et al. 2003) and 
although LH and estradiol were positively correlated with the intensity of potency 
disturbances (Härkönen et al. 2003), there were fewer men with this hormonal 
condition (LH > 6.0 IU/L and T > 9.8 nmol/L) among those having > 23 
androgen receptor (AR) CAG repeats compared with others (Härkönen et al. 
2003). These same men with > 23 AR CAG repeats reported decreased potency 
less often than other men (Härkönen et al. 2003). Thus, it seems to be so that 
the potency is not regulated similarly in all men. There may be genetic sub-
groups among men in this respect. Regarding this, it is very interesting that the 
HAP4 AR haplotype has been reported to be associated with an increased risk 
for male infertility, although AR CAG repeat number was not different among 
infertile and control groups of men (Saare et al. 2008). Furthermore, it has been 
shown that in the females AR CAG repeat number is smaller among patients 
with premature ovarian failure (Laisk et al. 2010) and that AR CAG repeat 
number variations and X-chromosome inactivation pattern exert an effect on 
LH and FSH levels, supporting thus clearly the necessity of taking the genetic 
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variables into account in any analysis of the reproductive functions, including 
analysis of the potency disturbances.  
Although it is clear by now that LHCG receptor together with cAMP and 
CREB, the components of the signal transduction pathway used by LH, are 




6.2 Strengths and limitations 
To the knowledge of the author, the presence of the LH receptor in the penis has 
not been previously investigated. This study may provide a basis for a better 
understanding of penile tissue function in the future. Based on the results, it is 
clear that further research is needed in this area to investigate the role of the LH 
receptor in the penis.  
One of the main limitations of the study, performed on human penis tissue, 
were the small number of patients the tissue samples were taken from. Only 
three penises were used for immunohistochemistry to detect the LH receptor 
and the components of its signal transduction pathway in the penis.  
Another limitation may be the fact that penile tissue was taken from elderly 
cancer patients. This raises the question whether the treatment of cancer or the 
cancer itself may affect the outcome of the study. The use of human penile tissue 
in studies is limited due to difficult availability, not to mention the availability 
of healthy penis tissue. Furthermore, a strict legislation on using cadaver material 
for research purposes, the necessity of immediate removal of the tissues after 
death and the legal-ethical requirements, especially getting informed consent 
before death and sample-taking, and the limited possibility of getting material 
from sex assignment surgery, restrict studying the human penile tissue. For this 
reason, only one type of method was used to demonstrate LH in the human 
penile tissue, but this was considered sufficient, because the used antibody itself 
had already been tested using several methods in the mouse. On the other hand, 
we got the same results for LH receptor in the young healthy mouse penis tissue 
by using three different study methods and the same primary antibody for 
immunohistochemistry. The LH receptor was present in both the mouse and the 
human penises mostly in the same cell types.  
 
 
6.3 Future perspectives 
Further functional studies are indicated to determine the possible roles of LH in 
the penis and to evaluate whether it may be involved in the pathogenesis of 
erectile dysfunction. These functional studies could include e.g. electron micro-
scopy on transfer of gold particle-labelled hCG to the penile interstitial tissue, 
as in the testis, hCG/LH seems to be actively transported through the endothelium 
of the testicular microvessels, i.e. in a receptor-mediated way (Ghinea et al. 
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1994; Ghinea and Milgrom 2001), and treatment with a low dose of ovine LH 
or inducing an endogenous LH peak by mating results in leucocyte 
accumulation and vascular leakage of carbon in the testis (Bergh et al. 1990), 
suggesting that more research on the vascular regulation of the erectile 
mechanisms by LH is necessary to understand the mechanisms of potency 
disturbances in aging men. If LH is transported actively – in a receptor-
mediated way – to the penile interstitial tissue and high LH levels are involved 
in the generation of potency disturbances among the aging men, blocking such 





1. The present study clearly shows the presence of the LH receptor in the 
mouse penis.  
2. LH receptor is present in the human penis. 
3. The components of LH signal transduction pathway, cAMP and CREB are 
expressed in the human penis. 
4. Based on the fact, that LH receptor and the components of its signal trans-
duction pathway are present in the penis, it is possible, that LH regulates the 
function of corpus spongiosum and cavernosum penis and may thereby 
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SUMMARY IN ESTONIAN 
Luteiniseeriva hormooni (LH) retseptori esinemine peenises ja selle 
võimalik roll erektsioonihäirete patogeneesis 
 
Sissejuhatus 
Seoses elanikkonna vananemisega arenenud riikides on erektsioonihäiretega 
seotud uuringud kaasaja teaduses aktuaalseks teemaks.  
European Male Ageing Study kohaselt esines erektsioonihäireid 30%-l uurita-
vatest. Esinemissagedus oli kõrgem vanemates vanuserühmades, eriti 70-aas-
taste ja vanemate meeste seas (64%) (Vasan, 2010). Kuni 1990. aastate alguseni 
arvati, et erektsioonihäired on seotud loomuliku vananemisprotsessiga, kuid 
ulatuslikud uuringud selles valdkonnas on näidanud, et see pole seotud ainult 
vanusega (Solomon jt, 2005). 
Märkimisväärselt suurel osal vanemaealistest meestest esineb erinevate 
suguhormoonide taseme muutusi. Neist levinum on subkliiniline hüpogonadism 
(seerumi LH > 6.0 U/l, seerumi testosteroon > 9.8 nmol/l), mida esineb 23%-l üle 
40-aastastest meestest ning mille esinemissagedus tõuseb proportsionaalselt 
vanusega (Härkönen jt, 2003; Veräjänkorva jt, 2003). P. Härköneni (2003) 
uurimisrühm Turku Aging Male keskusest on leidnud statistiliselt olulise posi-
tiivse korrelatsiooni LH taseme tõusu ja potentsi languse vahel. Võimalik, et 
vanemaealiste meeste kõrgenenud LH tase mõjutab peenise kude ning võib 
seeläbi olla seotud erektsioonihäirete tekkemehhanismidega. Selle eelduseks on 
LH retseptori esinemine peenises. 
Ajuripatsi eessagara gonadotropiin LH on üks tähtsamaid sugunäärmete 
talitluse reguleerijaid, mis avaldab toimet objektrakkudele nende rakumemb-
raanil olevate retseptorite kaudu. LH retseptorid kuuluvad G-proteiinide kaudu 
toimivate, seitse korda rakumembraani läbivate retseptorite geeniperekonda 
(Ascoli jt, 2002). LH retseptor on avastatud mitmetes ekstragonadaalsetes 




Uurimistöö põhieesmärgiks on selgitada LH retseptori ja LH signaali ülekand-
misega seotud molekulide olemasolu peenises.  
Sellest tulenevalt on eesmärgid järgmised: 
1. Määrata LH retseptori esinemine hiire peenise koes. 
2. Selgitada, kas LH retseptor on olemas inimese peenise koes. 
3. Määrata kahe LH signaali ülekandmisega seotud molekuli, cAMP-i ja 
CREB-i, olemasolu inimese peenise koes. 
4. Analüüsida saadud tulemuste põhjal, kas vanemaealiste meeste kõrgenenud 
seerumi LH tase võib mõjutada peenise spongioos- ja kavernooskeha funkt-
siooni ja olla seotud erektsioonihäirete patogeneesiga. 
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Materjal ja meetodid 
LH retseptori määramiseks hiire peenises kasutati järgnevaid uurimismeetodeid: 
immunohistokeemia, Western blotting ja kvantitatiivne RT-PCR. Peenise ja 
testise koe doonoritena kasutati Balb/c hiiri. Immunohistokeemias kasutati 14 
hiire kude (6–7 nädala vanused), Western blottingus 20 hiire kude (10–12 nädala 
vanused) ning kvantitatiivses RT-PCR-s 8 hiire kude (15 nädala vanused). 
LH retseptori määramiseks inimese peenises kasutati kolme Tampere Üli-
kooli Haigla patsiendi peenise kude. Kahel patsiendil (66- ja 64-aastane) oli 
diagnoositud pärasoole vähk sekundaarsete peenise metastaasidega ning neile 
teostati täielik penektoomia. 83-aastasel patsiendil oli diagnoositud peenise 
skvamoosrakuline kartsinoom ning teostati osaline penektoomia. Uurimis-
meetodina kasutati immunohistokeemiat.  
LH retseptori ja LH signaali ülekandjate (cAMP ja CREB) määramiseks 
peenise spongioos- ja kavernooskoes kasutati samade patsientide peenise kude, 





Positiivne immunoreaktsioon LH retseptorile esineb hiire peenise ureetra 
epiteelis ning peenise spongioos- ja kavernooskeha kavernoossete tühimike 
endoteelirakkudes. Positiivsed tulemused leiti kõikides uuritud peenistes. Nega-
tiivsetes kontrollides positiivset immunoreaktsiooni ei esine. Testise kude kasu-
tati positiivseks kontrolliks ning saadi positiivne immunoreaktsioon LH retsep-
torile Leydigi rakkudes ja seemnetorukeste kesksetes osades valendiku lähedal. 
Positiivsed tulemused saadi ka Western blottingu ning kvantitatiivse  
RT-PCR-i uuringutega. 
Inimese peenise koes saadi positiivne immunoreaktsioon kõikides uuritud 
peenistes. Positiivne immunoreaktsioon esineb peenise spongioos- ja kaver-
nooskeha kavernoossete tühimike endoteelirakkudes ja spongiooskeha interstit-
siaalse koe fibroblastoidsetes rakkudes. Positiivne immunoreaktsioon on nähtav 
ka glans penis’es ureetra epiteeli pindmise, vahepealse ja basaalse kihi rakkudes, 
kavernoossete tühimike endoteelirakkudes ning interstitsiaalse koe fibroblastoid-
setes rakkudes. Positiivne immunoreaktsioon esineb ka kapillaariseinte endo-
teelirakkudes. Negatiivsetes kontrollides positiivset immunoreaktsiooni ei leidu.  
Positiivne immunoreaktsioon cAMP-ile esineb enamikes ureetra epiteeli 
pindmise, vahepealse ja basaalse kihi rakkudes ning interstitsiaalse koe fibroblas-
toidsetes rakkudes. Positiivne immunoreaktsioon on nähtav ka peenise spongioos- 
ja kavernooskeha kavernoossete tühimike endoteelirakkudes ja kavernooskeha 
interstitsiaalse koe fibroblastoidsetes rakkudes. 
Positiivne immunoreaktsioon CREB-ile esineb ureetra epiteeli pindmises ja 
vahepealses kihis ning mõningal määral peenise spongiooskeha kavernoossete 
tühimike endoteelirakkudes ja interstitsiaalse koe fibroblastoidsetes rakkudes. 
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Positiivne reaktsioon on nähtav ka peenise kavernooskeha kavernoossete 
tühimike endoteelirakkudes ning interstitsiaalse koe fibroblastoidsetes rakkudes. 




1. Käesolev uuring näitab selgelt LH retseptori olemasolu hiire peenise koes. 
2. LH retseptor esineb inimese peenise koes. 
3. Kaks LH signaali ülekandmisega seotud molekuli, cAMP ja CREB, esinevad 
inimese peenise koes. 
4. Lähtudes asjaolust, et peenises on olemas nii LH retseptor kui ka selle sig-
naaliülekande molekulid, on võimalik, et LH reguleerib peenise spongioos- 
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